Zacks Investment Research upgraded shares of Pfenex Inc (NYSEMKT:PFNX) from a strong sell rating to a hold rating in a report published on Wednesday.
According to Zacks, “Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf?nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California. “
Several other equities analysts also recently weighed in on PFNX. ValuEngine downgraded Pfenex from a hold rating to a sell rating in a research report on Tuesday, August 1st. William Blair reissued an outperform rating on shares of Pfenex in a research report on Thursday, August 10th.
Shares of Pfenex (NYSEMKT:PFNX) remained flat at $3.04 on Wednesday. 67,925 shares of the company were exchanged. The stock has a 50 day moving average price of $3.25 and a 200-day moving average price of $4.20. Pfenex has a 1-year low of $2.94 and a 1-year high of $11.35. The firm has a market capitalization of $71.53 million, a price-to-earnings ratio of 49.03 and a beta of 4.65.
Pfenex (NYSEMKT:PFNX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $3.10 million. Pfenex had a negative net margin of 406.87% and a negative return on equity of 75.61%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.43) earnings per share. Equities analysts predict that Pfenex will post ($2.09) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Pfenex Inc (PFNX) Upgraded to Hold at Zacks Investment Research” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2017/10/12/pfenex-inc-pfnx-upgraded-to-hold-at-zacks-investment-research.html.
Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Pfenex by 221.0% during the first quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 22,160 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Pfenex during the second quarter worth $252,000. Susquehanna International Group LLP acquired a new stake in shares of Pfenex during the second quarter worth $272,000. Goldman Sachs Group Inc. boosted its holdings in shares of Pfenex by 126.7% during the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 31,308 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new stake in shares of Pfenex during the first quarter worth $439,000.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.